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HPLCAbstract In the present study, a novel divalproex sodium (DS) enteric-coated capsule was
prepared, and high performance liquid chromatography (HPLC) assay method for DS was devel-
oped. Their uniformity, release curve and release characteristics in different solvents were examined.
The release studies were performed using marketed sample as a reference and data were analyzed in
terms of cumulative release amounts as a function of time. It was demonstrated by the results that
assay developed was speciﬁc, rapid and reliable, which can be used to determine DS in vitro
accurately, and our developed samples were similar to reference preparation in in vitro release
characteristics. The release characteristics of different batches of samples were quite similar to each
other, and the total release percents of DS from enteric-coated capsule were within 0–10% in HCl,
and reached close to 100% in phosphate buffer. Similarity factors (f2) of three batches between two
preparations were all higher than 50. The developed enteric-coated capsule may be a promising
alternative dosage form for treatment of related diseases.
 2016 The Authors. Production and Hosting by Elsevier B.V. on behalf of King Saud University. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bipolar disorder (BD) is a severe psychiatric disorder with
worldwide lifetime prevalence estimated between 0.3% and1.5%. It was reported that BD affects over 2% of the popula-
tion (Suppes et al., 2005). The natural course of BD is charac-
terized by acute severe affective episodes followed by high rates
of relapse and recurrence. Depressions occur with greater fre-
quency and last longer in BD, and even in treated samples,
patients with BDs spend one-third to one-half of their lives
with depressive symptoms. Furthermore, depression is associ-
ated with impairment in functioning that is at least equal to
that observed in mania (Dutta et al., 2002; Kakkar et al.,
2009). Thus, effective treatments for BD depression are
urgently needed to reduce suffering and improve quality of life
in patients, and the primary goal of treatment was to treat the
acute episode as well as to prevent recurrences. Although
numerous effective treatment options are available for acute
mania, few medications have consistently been demonstrated
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The treatment of BD remains a challenge for physicians.
To improve clinical outcomes for signiﬁcant number of
patients with BD, anticonvulsants and atypical antipsychotics
are often used as alternatives or augmentation strategies to
lithium. Divalproex is the most commonly prescribed anticon-
vulsant medication for patients with BD. Divalproex has
demonstrated efﬁcacy in preventing depressive episodes during
maintenance treatment, but it is not routinely prescribed for
the treatment of acute BD depression, and there is a perception
among clinicians that there is little evidence to support its use
(Muzyk et al., 2010). Divalproex has proven efﬁcacy in treat-
ing acute mania and remains the principally accepted anticon-
vulsants for effective antimanic therapy. Approved for the
treatment of mania in 1995, divalproex has surpassed lithium
as the primary mood stabilizer employed in the treatment of
bipolar disorders whether as monotherapy use or as a compo-
nent of combination therapy regimens (Taher et al., 2009).
As a formulation combining valproic acid and sodium val-
proate, divalproex sodium (DS) is indicated for use as sole and
adjunctive therapy in the treatment of patients with complex
partial seizures that occur either in isolation or in association
with other types of seizures. DS is also indicated for use as sole
and adjunctive therapy in the treatment of simple and complex
absence seizures, and adjunctively in patients with multiple sei-
zure types that include absence seizures. However, there are
several limitations of traditional routes of DS delivery
(Pavuluri et al., 2004; Reed et al., 2009). These limitations
include low oral bioavailability due to degradation in the
stomach, inactivation and digestion by proteolytic enzymes
in the luminal cavity, poor permeability across intestinal
epithelium because of its high molecular weight and lack of
lipophilicity.
Currently, the formulations of DS on the market in China
are mainly normal tablet or capsule. However, these types of
general formulations have a common drawback. Therefore, a
large number of attempts have been made to deliver divalproex
sodium orally using enteric-coated capsules. The enteric-
coated capsules, which have a special outer covering designed
to dissolve and absorb in the small intestine, offer the advan-
tage of once daily dosing which may improve patient compli-
ance and provide the opportunity to titrate to maximum
effective dose while possibly reducing the risk of peak-
concentration related side effects (Hosny et al., 2002). This fea-
ture of enteric-coated preparation not only moderates the
stomach irritation or neutralizes gastric acid aroused by the
long-term use of DS, but also improves the interrelated food
absorption and avoids some adverse reactions (Pierre-Louis
et al., 2009).
The aim of this study was to develop a novel DS enteric-
coated dosage. In vitro dissolution testing is frequently used
to determine the release characteristics of the pharmaceutical
products over time. On this basis, a dissolution assay method
was established and validated to the in vitro release study for
enteric-coated capsules by high performance liquid chro-
matography (HPLC). The dissolution proﬁles of the commer-
cial and self-made ones are compared by similar factors
method, to evaluate the drug release performance of the devel-
oped formulation.2. Materials and methods
2.1. Chemicals and reagents
The reference substances of DS (purity > 99.5%) were
obtained from the Sigma–Aldrich (Shanghai, China). Potas-
sium dihydrogen phosphate and sodium hydroxide were pro-
vided by Qinjiuhong chemical reagent Co., Ltd. (Zhengzhou,
China). Hydroxy-propyl methyl cellulose (HPMC), microcrys-
talline cellulose (MCC) and ethyl cellulose (EC) were provided
by Beijing huajinsheng technology co., Ltd. The commercial
product (Razadyne ER) was purchased from the market.
Chemicals of analytical grade were provided by Nanjing chem-
ical reagent Co., Ltd. (Nanjing, China). Water was distilled
and puriﬁed using a Milli-Q System (Millipore, MA, USA).
2.2. Development of assay method for DS
HPLC assay method was developed to determine DS (Li and
Yang, 2014).
2.2.1. Chromatographic analytical procedures
The chromatography separation was performed with a Dia-
monsilTMC18 Column (200 mm  4.6 mm, 5 lm), the ﬂow rate
was 1.2 ml min1, with column temperature of 25 C, the
mobile phase was citrate buffer–phosphate buffer–acetonitrile
(35:35:30, with the pH of 3.0 ± 0.1, adjusted by phosphoric
acid), and the drug was detected at 210 nm for determining
the content of DS.
2.2.2. Linearity
The developed capsules were 125 mg standard in DS, and the
total volume of release medium was 500 ml. Its release percent
should be within 0–10% in acid, and the maximum release
should reach 100% in buffer solution.
The appropriate amounts of DS was weighed precisely and
dissolved in phosphate buffer solution, to prepare the testing
solutions of different concentrations. The testing solutions of
different concentrations were taken for HPLC analysis. The
calibration curve samples were assayed in triplicate, using con-
centration (C) as abscissa (X) and peak area as ordinates (Y).
2.2.3. Precision and accuracy
Precision was investigated by determining the replicate QC
samples of 100% concentration level in recovery determination
experiment on one day and three consecutive days, described
as intra-day and inter-day precision, respectively. Accuracy
was assessed by relative error and precision was investigated
by intra- and inter-day relative standard deviation (RSD).
2.2.4. Recovery
Absolute recovery of DS was investigated by QC samples, and
results were evaluated by comparing the means from the excip-
ients solution spiked with reference solution with those of the
standard samples. Three concentration levels of analytes were
estimated by analyzing the samples at each level.
Table 1 Determination result of recovery.
Concentration
(%)
Addition
(mg)
Mass
yield
(mg)
Recovery
(%)
Mean
(%)
RSD
(%)
50 12.9 12.70 98.47 99.31 0.94
13.1 13.04 99.58
13.3 13.43 100.97
80 21.3 20.97 98.44
21.0 20.88 99.45
21.6 21.31 98.66
100 25.9 25.90 100.02
26.0 26.01 100.04
25.8 25.33 98.18
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The stability of DS was investigated using the phosphate buf-
fer solution at the concentration of 250 lg ml1. The samples
were analyzed at 0, 2, 4, 6 and 8 h after conditioning at room
temperature, respectively.
2.3. Dissolution assay method for enteric-coated capsules
The oar method for dissolution test was applied to determine
dissolution of DS from enteric-coated capsules (Yang and
Li, 2014). The quantity of 500 ml HCl solution was ﬁrstly used
as release medium to take to dissolution glass at predetermined
temperature; then, it was agitated by stirring blades at the rota-
tion speed of 50 r min1 and sampled at the scheduled time
after initiating experiment. After 2 h the solution was ﬁltered
and the subsequent ﬁltrate was used as test solution in acid;
500 ml of phosphate buffer solution was then added and used
as release medium. After 45 min the solution was ﬁltered and
the subsequent ﬁltrate was used as test solution in buffer.
The concentration of DS at each time point was determined
by HPLC assay. Meanwhile the proper amounts of valproic
acid standard reference were taken and dissolved in acetoni-
trile, and then diluted by 0.1 mol L1 HCl solution or phos-
phate buffer solution (pH 7.5) to the ﬁnal concentration of
250 lg ml1, which was used as control solution, which was
used as standard solution for the total drug amounts (W).
The above solutions were analyzed by external standard
method, and accumulative release amounts and release percent
were calculated according to the formula:
Qn ¼ CnV0 þ
Xn1
i¼0
CiVi
Accumulative release percent ð%Þ ¼ Qn=W 100%
Noting: Qn was the accumulative release amounts at each
time point, Cn was the measured concentration at each time
point, V0 was the bulk volume of release medium, Vi was the
sampling volume, Ci was the measured concentration at time
point i, and W was the total drug amounts in capsules.
2.4. Release uniformity of DS in different medium
The in vitro release feature of DS was assessed in 0.1 M HCl,
phosphate buffer (PBS, pH 7.5), respectively. The solution
samples were taken for dissolution determination at 2 h in
HCl, and at 10, 20, 30, 45 and 60 min following the assay pro-
cedures described above in PBS. Filtrate was taken to deter-
mine the accumulative release amounts at each time point
and draw the release curve.
2.5. Drug release study and statistical analysis for release data
The developed formulation and marketed product were both
taken for dissolution determination with the above two solu-
tions used as release medium, respectively. Accumulative
release percents were calculated for both the preparations
and release performance in each medium was contrastively
evaluated.
According to the guideline for bioavailability and bioe-
quiavailability of orally administered solid drugs, similarity
(f2) measuring was applied to evaluate the closeness betweenthe two dissolution proﬁles. The f2 was calculated according
to the equations given below:
f2 ¼ 50 lg½ð1þQ=nÞ1=2  100 Q ¼
Xn
t¼1
ðRt  TtÞ2
where n is the number of time points, and Rt and Tt are the
percentages of the reference and testing drug release at each
time point t, respectively. In order to consider the release pro-
ﬁles similar, the f2 values should be close to 100. In general, f2
value of the two drug release proﬁles is between 50 and 100,
and then these two drug release characteristics are similar,
whereas value below 50 indicates differences between the
release proﬁles.3. Results
3.1. Method validation
3.1.1. Specificity
It was indicated by the HPLC chromatograms of valproic acid
that its retention time (RT) was about 14.082 min, and enteric
ﬁlm coating was eluted at 4.3 and 6.9 min, without interfering
the determination.
3.1.2. Linearity
The calibration curves were prepared at the concentration
levels of 25.2–252 lg ml1 in phosphate buffer. The typical
curve equations were constructed with a weight of 1/x2 and
described as A= 7.8368C+ 0.1319, with the correlation coef-
ﬁcients (r) of 0.9999.
3.1.3. Precision and accuracy
The results of precision and accuracy were assessed at low,
median and high levels. The RSD values of intra- and inter-
day precision were within 1%, and accuracy results extended
from 95% to 105%.
3.1.4. Recovery
Absolute recovery of DS was determined by comparing the
contents of three-level QC samples incorporated with excipi-
ents to those of the standard solutions which were directly
diluted by release medium. The recovery at low, middle and
high QC concentrations was shown in Table 1. All these results
Figure 1 Release curve of DS in enteric-coated capsules in
phosphate buffer. Each point represents average ± standard
deviation (n= 6).
Table 3 The in vitro release rates of DS from enteric-coated
capsules.
Batch Release rate (%)
2 h in HCl 45 min in phosphate buﬀer
20150507 5.7 91.9
20150509 6.3 92.0
20150511 7.7 91.6
Figure 2 The release curve of the developed testing and
marketed reference enteric-coated samples, with phosphate buffer
(pH 7.5) as the release medium in the different stages in
experiment.
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analysis of in preparation.
3.1.5. Stability
The room temperature stability results of DS with the RSD
values lower than 2% showed that the testing samples were
stable under storage conditions and routine analysis for release
study.
3.2. Release uniformity of DS in different medium
The release results of DS in two medium are shown in Table 2
and Fig. 1, respectively. It can be drawn that the accumulative
release percents calculated in different medium were different.
In 0.1 M HCl, the drug release amounts were below 10% at
2 h. In phosphate buffer, the drugs can be fully released and
the release percents all reached above 95%. Furthermore, the
release rates were all consistent with each other both in the
two medium, suggesting that DS was released with nearly
the same property, and dissolution increased continuously
along with the time. Thus it was indicated that there was little
effect from release medium on the release performance of
enteric-coated capsules.
3.3. Release rate determination for enteric-coated capsules
The release results of DS from enteric-coated capsules are sum-
marized in Table 3. It showed that the total release percent was
within 0–10% in HCl, and reached close to 100% in phosphate
buffer, which met the requirement for release rate determina-
tion of oral enteric-coated preparation.
3.4. Drug release study
The dissolution curve of developed formulation and marketed
product in phosphate buffer is shown in Fig. 2. The similarity
factors (f2) were calculated for the formulations using the
release proﬁle with the marketed product as the reference.
The f2 values of three batches were all higher than 50 (87.1,
76.4, and 70.5, respectively), suggesting that their release pro-
ﬁles were quite similar to those of the reference.
4. Discussion
In the in vitro release determination, in total two solutions,
0.1 M HCl solution and phosphate buffer (pH 7.5) were
selected as release medium. Nevertheless, the drugs were
released from enteric-coated capsules under mild alkaline con-
dition, and thus sink condition experiment for medium was
performed in phosphate buffer (Cui et al., 2015; Xue et al.,
2014). Preparation method resembles the Divalproex SodiumTable 2 The in vitro release result of DS in HCl at 2 h.
Batch 1 2 3 4 5 6 Mean
20150507 6.76 5.06 6.70 4.50 6.25 4.95 5.71
20150509 6.57 5.60 6.48 6.83 5.97 6.22 6.28
20150511 7.58 7.19 8.20 8.15 7.31 7.56 7.66Delayed-Release Tablets (USP32). In brief, monopotassium
phosphate and sodium hydrate were dissolved in 5000 ml
deionized water, pH was adjusted to 7.4 ± 0.1 with HCl
(0.08 M), and the solution was then diluted to 6000 ml. In
phosphate buffer above, 936 mg valproic acid standard sample
was precisely weighed and dissolved into the 500 ml (7 folds of
raw material drug amounts equivalent to standard amount be
dissolved in the same volume of release medium) (Pradhan
et al., 2014; Singh and Kim, 2000). The experimental results
showed that DS could well be dissolved in release medium;
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requirement of drugs in enteric-coated capsules.
For the drug release mechanism in matrix formulations, it
can be decided by the formula: Q= Ktn, where n is the release
exponent value. Practically speaking, in cylindrical formula-
tions, n value is lower than 0.45 suggesting the drug release
was corresponding to the Fichian diffusion, and higher than
0.89 suggesting the drugs were released by matrix corrosion
pathway (Peng et al., 2014). Whereas the characteristic param-
eter n is between 0.45 and 0.89, the main release mechanism of
drugs from solid preparations was non-Fichian diffusion
(Peppas, 2014). In this study, the n value for both the devel-
oped formulation and marketed product was 0.62 and 0.73,
respectively, indicating that the drug release mechanism fol-
lowed the non-Fick diffusion, which was affected by the drug
diffusion and matrix corrosion (Le et al., 2014).
In conclusion, we prepared DS enteric-coated capsules, and
developed an analysis method for the quantiﬁcation and
in vitro release study of DS. The results showed this assay
method had highly convenience and reliability for the rapid
quantitative determination of DS concentration in high-
throughput release characteristic studies. Furthermore, the
drugs could be well released from enteric-coated capsules in
release medium within the speciﬁed time limit, and the release
characteristics of the developed formulation and commercial
samples were quite consistent with each other.
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